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1. INTRODUCTION 
Laminin (Mr 900000) and fibronectin (&& 
440000) are noncollagenous glycoproteins of the 
extracellular matrix, both known to promote cell 
adhesion and to bind to heparin and related 
sulfated glycosaminoglycans [ 1,2]. Fibronectin is 
characterized by its multiple additional interac- 
tions such as those with Staphyfococcus aureus [3], 
fibrin [4], collagens and gelatin [5] and C-reactive 
protein [6]. Fibronectin, which unlike laminin also 
occurs in plasma and other body fluids [2,4], is 
well known for its high susceptibility to various 
proteinases [7,8], while laminin has been found to 
be relatively resistant [7,9, lo]. We here report that 
immobilized laminin binds plasminogen and its 
tissue-type activator; these interactions may have 
significance in the proteolytic cleavage of laminin 
in vivo. 
2. MATERIALS AND METHODS 
2.1. Materials 
Laminin was purified from EHS mouse tumor, 
rich in basement membrane material as in [l ,111. 
Plasminogen prepared from Cohn supernatant I
Abbreviations: BSA, bovine serum albumin; PBS, 
0.01 M phosphate-buffered 0.15 M saline, pH 7.4; PU, 
Plough unit(s); SDS-PAGE, sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis; t-PA, tissue-type 
plasminogen activator; u-PA, urokinase-type PA; 
Tween, polyoxyethylene sorbitane monolaureate 20 
~Iasminogen activator Pro teo~ysis 
fraction of human plasma was from Kabi 
(Stockholm) and contained 20 CU/mg. t-PA 
purified from culture medium of Bowes human 
melanoma cells [ 121 was a gift from Dr Desire Col- 
len and contained 62.5 /cg/ml(2566 PU/ml). u-PA 
was purified using benzamidine-Sepharose [131 
from a commercial preparation (Calbiochem, La 
Jolla, CA). Human serum albumin was from Kabi. 
The following rabbit antisera were used: anti- 
laminin [ 141, anti-plasminogen (Dako, Copen- 
hagen), anti-t-PA (a gift from Dr D. Collen) and 
anti-u-PA prepared as in [15] using benzamidine- 
Sepharose purified u-PA as antigen. Dow-Latex 
particles (diameter, 1.1 pm) were from Serva 
(Heidelberg, FRG). 
2.2. methods 
Polystyrene microtiter wells (immobilization 
area 0.65 cm2; Nunc, Roskilde, Denmark) or tubes 
(1.73 cm2; Labsystems, Helsinki) were coated 
from a solution of 2 pg/ml protein in PBS using an 
overnight incubation at room temperature. 
Radioiodination of protein was performed as in 
[ 161 using 12? (Amersham) in a modification of the 
chloramine-T method. The spec. act. was 
2.5 &i/pg. In the binding experiments coated 
wells (or tubes) received 75 ~1 (or 200~1) of the 
protein solution diluted in PBS-Tween sup- 
plemented with 4% (w/v) polyethylene 6000 
(Fluka, Buchs, Switzerland) known to speed up 
solid-phase protein-protein interactions [ 171. The 
incubation was for 120 min at room temperature 
and was followed by repeated washes with PBS- 
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Tween and H20. Enzyme immunoassays with 
predetermined ilutions of the specific rabbit an- 
tisera, and alkaline-phosphatase labeled swine 
anti-rabbit IgG (Orion Diagnostica, Espoo, 
Finland) were as in 161. 
For SDS-PAGE we used polyacrylamide gra- 
dient (5-16%) slab gels under nonreducing condi- 
tions as in [18] using autoradiography for 1251- 
labeled samples. Coated latex particles were 
prepared by incubating 500 ,J of 2% (w/v) par- 
ticles with an equal volume of lOO~g/ml of pro- 
tein solution in 0.1 M Na-glycine-buffered 0.15 M 
saline (pH 8.2) for 2 h at 37°C and centrifugation 
and washing as in [6]. 
3. RESULTS AND DISCUSSION 
Immobilization of laminin onto polystyrene sur- 
face was quantitated using ‘251-1abeled laminin. A 
large proportion of the laminin added was im- 
mobilized, e.g., from 10 pg in 200 ,~l 86% bound 
and from 3.2pg 30%; a coating concentration of 
Fig. 1. Interaction between immobilized laminin and 
soluble piasminogen. Polystyrene wells containing 
270 ng laminin per 1.73 cm” received different 
concentrations of unlabeled (0) or ‘251-labeled (0) 
plasminogen for 2 h at room temperature. The bound 
plasminogen was determined using radioactivity for “‘I- 
labeled plasminogen and EIA for both labeled and 
unlabeled plasminogen. As a control, wells coated with 
human serum albumin (A) or uncoated wells (0) were 
used in similar binding experiments. Different amounts 
of [‘251]plasminogen (g-2000 ng/ml) were incubated 
with a constant amount (270 ng/1.73 cm*) of laminin 
coated to the polystyrene surface. The inset shows 
Scatchard plot of the binding of [‘251]plasminogen to
Fig.2. Binding of laminin to plasminogen-coated Latex 
particles. A volume of 10 pl laminin solution containing 
1.25 pg (A) or 300 ng (B) PBS-Tween buffer was 
incubated with an equal volume of plasminogen-coated 
Latex particles and photographed within 5 s. As a 
control, 10 pl laminin (5 pg) was incubated with 10 ~1 
BSA-coated Latex particles and photographed (C). 
solid-phase laminin. Magnification x 5. 
400 ng/200pl was chosen, from which 270 ng 
(0.30 pmol, 67%) bound per 1.73 cm2 surface area 
in each tube, for all subsequent experiments. 
Soluble plasminogen added was found to bind to 
the immobilized laminin. This binding was dose- 
dependent and was demonstrated using both 
[‘251]pIasminogen, unlabeled plasminogen and en- 
zyme immunoassay (fig. 1). The dissociation cons- 
tant (&) (n = 9) for the labeled plasminogen using 
Scatchard plot analysis (fig.1, inset) was 2.8 x 
lo-’ M. Values calculated from plots of l/A vs 
l/c (A, absorbance value at 405 nm; c, concentra- 
tion) for labeled and unlabeled plasminogens (see 
fig.1) were & = 6.7 x 10e8 M and & = 3.0 X 
10s9 M, respectively. The difference in these 
values indicates that the radioiodination procedure 
had affected the binding or antigenic properties of 
plasminogen. Maximally, each mol of immobilized 
laminin bound 12.7 mol ~1251]plasminogen, What 
is not shown in fig. 1, is that if >500 ng laminin 
was immobilized per tube, the binding of 
plasminogen was much lower, suggesting that the 
higher density of laminin molecules causes steric 
hindrance. 
The interaction between laminin and plasmin- 
ogen was also demonstrated using Latex agglutina- 
tion tests as documented in fig.2. The agglutina- 
tion of plasminogen-coated Latex particles by 
laminin shows that i has at least 2 binding sites for 
plasminogen per molecule. 
Of the two types of plasminogen activators used, 
t-PA but not u-PA was bound by immobilized 
30 
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10x 500 260 125 63 31 16 0 4' 
ng/rnl 
Fig.3. interaction between immobilized iaminin and 
soluble plasminogen activators. Conditions identical to 
those in fig.1 were employed to study the binding of t- 
PA (0) and u-PA (0), which were determined using 
EIA. As a control, wells coated with albumin (A) or 
uncoated wells (0) were used. 
laminin (fig.3). The binding of both plasminogen 
and t-PA occurred both in the presence of 0.1% 
Tween and in the presence and absence of 
polyethylene glycol. No binding to uncoated or 
albumin-coated surfaces was found. Fig.4 shows 
that laminin is cleaved in the presence of 
plasminogen and either type of activator but not in 
the presence of plasminogen or the activators 
alone. 
The observed interactions between plasminogen, 
t-PA and immobilized laminin and the cleavage of 
laminin by activated plasmin suggest a mechanism 
for its regulated proteolysis. It should be noted 
that under the conditions used the cleavage of 
laminin was relatively slow if compared to that of 
fibronectin. Nevertheless, it seems that laminin 
does not inhibit t-PA from activating plasmin- 
ogen. 
Neuroblastoma cells are known to produce both 
laminin [19] and PA [20], which at least in some 
cell lines is t-PA (unpublished). Interestingly, cell- 
associated PA of tumorigenic rat neuroblastoma 
cells was suppressed by substratum-attached 
matrix material of nontumorigenic neuroblastoma 
cells with little or no PA activity 1201. 
Fig.4. Cleavage of [‘2sI]laminin by plasminogen 
activated with PA. The indicated mixtures in PBS were 
incubated in an end-over-end mixer at 37°C for 48 h and 
then analyzed by SDS-PAGE under reducing conditions 
followed by autoradiography. Lane 1, [‘251]laminin 
(20 gg); lane 2, [“‘I]laminin (2Ofig) + plasminogen 
(5 ag); lane 3, [‘251]laminin (2Opg) + u-PA (20 mPU); 
lane 4, [‘2’I]iaminin (20pg) + t-PA (20 mPU); lane 5, 
[‘2sI]Iaminin (20/1g) + plasminogen (5 pg) + u-PA 
(20 mPU); lane 6, [‘2sI]laminin (20pg) + plasminogen 
(5 pg) + t-PA (20 mPU). M shows the molecular masses 
of 14C-labeled marker proteins in kDa. 
We have no explanation for the differential bin- 
ding between the two activators t-PA and u-PA to 
laminin. They are distinct entities with differences 
in antigenic and molecular properties [ 121. A stri k- 
ing difference of possible relevance for our obser- 
vations is that t-PA but not u-PA binds to fibrin, 
which greatly enhances its ability to cleave 
pl~minogen [21]. It remains to be determined 
whether the binding of t-PA to laminin has any 
relationship to its binding to fibrin. 
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